ate phase II clinical study of intra-arterial chemotherapy using SM-11355 in patients with hepatocellular carcinoma (HCC) .
Phase 2
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-jRCT2080220093
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
-HCC confirmed histologically and/or clinically diagnosed by angiography and CT
-Hypervascular HCC
-Not indicated for hepatectomy, PEI, PMCT and RFA
-Stage II or III (Liver Cancer Study Group of Japan: Classification of primary liver cancer)
-ECOG performance status (PS) of 0, 1 or 2
-Aged 20 to less than 75
etc.
-Patients with a history of severe allergy to iodine-containing drugs and/or contrast media
-Severe complication (especially severe thyroid or heart disease)
-Active malignancies of other organs
etc.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method